CD95-Mediated Apoptosis in Acute Myeloid Leukemia (AML): Dependence on Maturational Stage and Growth Characteristics in Vitro
暂无分享,去创建一个
[1] Shigeki Tanaka,et al. Fas/APO‐1 (CD95)‐mediated cytotoxicity is responsible for the apoptotic cell death of leukaemic cells induced by interleukin‐2‐activated T cells , 1997, British journal of haematology.
[2] J. D. Young,et al. Lymphocyte-mediated cytolysis and disease. , 1996, The New England journal of medicine.
[3] Seok Lee,et al. Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy , 1996, British journal of haematology.
[4] C. Sebban,et al. Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia. , 1996, Leukemia.
[5] S. Farrow,et al. New members of the Bcl-2 family and their protein partners. , 1996, Current opinion in genetics & development.
[6] A. N. Veselkov,et al. Submitogenic concentrations of anti-CD3 monoclonal antibody exert antiapoptotic effects in preactivated CD4+ but not CD8+ human T cells. , 1995, Cytokines and molecular therapy.
[7] A. Strasser,et al. Bcl‐2 and Fas/APO‐1 regulate distinct pathways to lymphocyte apoptosis. , 1995, The EMBO journal.
[8] Y. Komada,et al. Fas receptor (CD95)-mediated apoptosis is induced in leukemic cells entering G1B compartment of the cell cycle. , 1995, Blood.
[9] J. Harbott,et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. , 1995, Blood.
[10] D. Bradbury,et al. Comparative quantitative expression of bcl‐2 by normal and leukaemic myeloid cells , 1995, British journal of haematology.
[11] K. Takatsuki,et al. Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. , 1995, Blood.
[12] K. Takenaka,et al. Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. , 1995, Blood.
[13] J. Westendorf,et al. Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. , 1995, Blood.
[14] M. Pfreundschuh,et al. Tumor Therapy by Immune Recruitment with Bispecific Antibodies , 1995, Immunological reviews.
[15] W. Kast,et al. T‐Cell Immunotherapy of Tumors by Adoptive Transfer of Cytotoxic T Lymphocytes and by Vaccination with Minimal Essential Epitopes , 1995, Immunological reviews.
[16] N. Young,et al. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. , 1995, Blood.
[17] J. Harbott,et al. Clinical, morphologic, cytogenetic and prognostic implications of CD34 expression in childhood and adult de novo AML. , 1995, Leukemia & lymphoma.
[18] S. Nagata,et al. The Fas death factor , 1995, Science.
[19] Y. Shima,et al. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. , 1995, Blood.
[20] T. Takizawa,et al. Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. , 1994, Blood.
[21] P. Krammer,et al. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. , 1994, Journal of immunology.
[22] T. Kotani,et al. Expression of functional Fas antigen on adult T-cell leukemia. , 1994, Leukemia research.
[23] S. Nagata,et al. Purification and characterization of the Fas-ligand that induces apoptosis , 1994, The Journal of experimental medicine.
[24] John Calvin Reed. Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.
[25] Takashi Suda,et al. Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family , 1993, Cell.
[26] L. Owen-Schaub,et al. Fas/APO-1 expression and function on malignant cells of hematologic and nonhematologic origin. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[27] S. Nagata,et al. Effect of bcl-2 on Fas antigen-mediated cell death. , 1993, Journal of immunology.
[28] J. Lotem,et al. Control of programmed cell death in normal and leukemic cells: new implications for therapy. , 1993, Blood.
[29] T. Waldmann,et al. APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia. , 1993, Blood.
[30] J. Magaud,et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. , 1993, Blood.
[31] W. van Putten,et al. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. , 1993, The New England journal of medicine.
[32] B. Dörken,et al. APO‐1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: Correlation with bcl‐2 oncogene expression , 1993, European journal of immunology.
[33] T. Miyawaki,et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. , 1992, Journal of immunology.
[34] T. Yoshino,et al. Detection of bcl-2 protein and bcl-2 messenger RNA in normal and neoplastic lymphoid tissues by immunohistochemistry and in situ hybridization. , 1992, Blood.
[35] S. Korsmeyer. Bcl-2 initiates a new category of oncogenes: regulators of cell death. , 1992, Blood.
[36] L. Owen-Schaub,et al. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. , 1992, Cellular immunology.
[37] M. Pierotti,et al. bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. , 1992, Blood.
[38] P. Möller,et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. , 1989, Science.
[39] S. Yonehara,et al. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor , 1989, The Journal of experimental medicine.
[40] W. Hiddemann,et al. Ambiguous phenotypes and genotypes in 16 children with acute leukemia as characterized by multiparameter analysis. , 1988, Blood.
[41] Y. Tsujimoto,et al. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[42] G Flandrin,et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[43] H. Gralnick,et al. Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.
[44] P. Krammer,et al. Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent anti-apoptotic program. , 1995, Leukemia.
[45] C. Thompson,et al. Bcl-2 and Bcl-2-related proteins in apoptosis regulation. , 1995, Current topics in microbiology and immunology.
[46] G. Majno,et al. Apoptosis, oncosis, and necrosis. An overview of cell death. , 1995, The American journal of pathology.
[47] G. Fleuren,et al. T-cell based cancer immunotherapy: direct or redirected tumor-cell recognition? , 1994, Immunology today.
[48] John Calvin Reed,et al. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[49] A. Wyllie,et al. Cell death: the significance of apoptosis. , 1980, International review of cytology.